Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
ATLANTA, Feb. 20, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , president and chief executive officer, will participate in the Credit Suisse London One-on-One Healthcare Conference on March 5 – 6, 2013 in London, UK.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
for Alimera Sciences
SOURCE Alimera Sciences, Inc.
More by this Source
Alimera Sciences Reports First Quarter 2013 Financial Results
May 09, 2013, 16:05 ET
Alimera Sciences Secures $20 Million Debt Facility
May 08, 2013, 08:00 ET
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
May 07, 2013, 16:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.